Clinical Study


Posted Date: Oct 26, 2020

  • Investigator: Trisha Wise-Draper
  • Specialties: Cancer, Head and Neck Cancer, Oncology
  • Type of Study: Drug

The purpose of this study is to determine anti-tumor activity by measuring overall response rate in recurrent and/or metastatic HNSCC patients receiving the combination of metformin and pembrolizumab.


To Be Eligible: Must Have Histologically Or Cytologically Confirmed Recurrent Or Metastatic Non-Cutaneous Hnscc, Ecog 0-2, No Nasopharyngeal Hnscc, No Chemo Or Rt Within 2 Weeks, No Previous Treatment With Pd-1 Or Pd-L1 Inhibitors, No Metformin In The Past 6 Months


Head And Neck Cancer

For More Information:

Uc Cancer Center

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.